Astel­las signs Asian li­cens­ing deal with Aquinox; Ar­a­vive touts ear­ly-stage PoC

→ Tokyo’s Astel­las Phar­ma has inked a li­cens­ing deal with Van­cou­ver’s Aquinox Phar­ma­ceu­ti­cal, snag­ging de­vel­op­ment and com­mer­cial­iza­tion rights for Aquinox’s lead drug can­di­date rosip­tor in Japan and oth­er Asia-Pa­cif­ic coun­tries. The as­set is a first-in-class, once-dai­ly oral treat­ment that’s cur­rent­ly in Phase III tri­als for in­ter­sti­tial cys­ti­tis/blad­der pain syn­drome in North Amer­i­ca and Eu­rope. As part of the deal, Aquinox will get $25 mil­lion in an up­front pay­ment, and up to $130 mil­lion in ad­di­tion­al mile­stones plus roy­al­ties.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.